Drug Profile
Thalidomide - Shanghai Pharmaceuticals Holding
Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Shanghai Pharmaceutical
- Developer Shanghai Pharmaceuticals Holding
- Class Antifibrotics; Antileprotics; Antineoplastics; Antitussives; Indoles; Phthalimides; Piperidones; Small molecules
- Mechanism of Action Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Ankylosing spondylitis
Most Recent Events
- 31 Mar 2017 No recent reports of development identified - Phase-II for Ankylosing spondylitis in China (PO)
- 01 Feb 2013 Phase-II clinical trials in Ankylosing spondylitis in China (PO)